ISTA Vitrase Spreading Agent Clears FDA; Full Launch Awaits New Vial
Executive Summary
ISTA Pharmaceuticals will delay full-scale launch of its spreading agent Vitrase until it receives approval for a more convenient vial form
You may also be interested in...
ISTA Vitrase Data Subgroup Analysis Could Support Efficacy, Cmte. Says
A subgroup analysis of Allergan/ISTA's Vitrase data could provide additional evidence for efficacy of the ophthalmic drug for treatment of vitreous hemorrhage, FDA's Dermatologic & Ophthalmic Drugs Advisory Committee said March 17
Wyeth Wydase discontinued
Wyeth has discontinued production of ocular surgery treatment Wydase (hyaluronidase). Wydase was manufactured at the company's Marietta, Penn. facility, which has been under an FDA consent decree since October 2000 (1"The Pink Sheet" Oct. 9, 2000, p. 3). Wyeth informed FDA of the discontinuation in the fourth quarter of 2000, but agreed to continue to manufacture the product until an alternate supplier of hyaluronidase was found...
Part D Discount Liability Coming Into Focus: CMS Releases Drug Cost Data
Newly released Medicare Part D data sheds light on the sales hit that branded pharmaceutical manufacturers will face when the coverage gap discount program gets under way in 2011